Michael Nofi, Chief Financial Officer of Edgewise Therapeutics, Inc. (NASDAQ:EWTX), sold 4,442 shares of common stock on November 10, 2026, for a total value of $201,786, according to a regulatory filing. The shares were sold at prices ranging from $45.165 to $45.57 per share, with an average price of $45.427. The stock currently trades at $46.53, just 0.95% below its 52-week high of $48.78, reflecting strong momentum with a 117% gain over the past year.
The sale was executed to cover statutory tax withholding obligations related to the vesting of restricted stock units (RSUs) and does not represent a discretionary sale by Mr. Nofi. Such transactions are common when RSUs vest, as companies often withhold shares to satisfy tax liabilities on behalf of executives.
On the same date, Mr. Nofi acquired 10,937 shares of Edgewise Therapeutics common stock through the vesting of RSUs. These RSUs were granted for no additional cash consideration, with each unit representing a contingent right to receive one share of common stock upon vesting. The RSUs are scheduled to vest in four equal annual installments beginning on November 10, 2026. Following these transactions, Mr. Nofi directly beneficially owns 6,495 shares of common stock and 32,813 derivative securities in the form of restricted stock units.
According to InvestingPro analysis, Edgewise holds more cash than debt on its balance sheet and maintains liquid assets that exceed short-term obligations. The platform offers 13 additional ProTips for EWTX, though current data suggests the stock may be overvalued relative to its Fair Value.
In other recent news, Edgewise Therapeutics has made several noteworthy announcements. The company presented Phase 1 data for its investigational oral small molecule cardiac sarcomere modulator, EDG-15400, at the Heart Failure Society of America 2026 Scientific Meeting. This follows the sale of its Sevasemten and muscular dystrophy business to Servier for $1.55 billion, allowing Edgewise Therapeutics to focus on cardiovascular disease. Raymond James responded to the company's end-of-phase-2 FDA feedback for EDG-7500 by raising the stock's price target to $85.00 and maintaining a Strong Buy rating. William Blair initiated coverage with an outperform rating and set a DCF-adjusted valuation of $53 per share. Additionally, H.C. Wainwright reiterated a Buy rating with a $57.00 price target. The company's lead asset, EDG-7500, is expected to begin Phase III studies in obstructive and nonobstructive hypertrophic cardiomyopathy in the fourth quarter of 2026. These developments highlight Edgewise Therapeutics' strategic focus on advancing its cardiovascular pipeline.